EGFR and non-small cell lung carcinoma: This limitation is significant in studies of NSCLC since actionable (responsive to tyrosine kinase inhibitors) exon 19 deletions in the EGFR oncogene are common in non-smoker NSCLC patients (mainly of the adenocarcinoma subtype).